Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
80.70B
Market cap80.70B
Price-Earnings ratio
17.92
Price-Earnings ratio17.92
Dividend yield
0.47%
Dividend yield0.47%
Average volume
915.41K
Average volume915.41K
High today
$773.85
High today$773.85
Low today
$748.18
Low today$748.18
Open price
$750.71
Open price$750.71
Volume
2.33M
Volume2.33M
52 Week high
$790.98
52 Week high$790.98
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

As of today, Regeneron(REGN) shares are valued at $767.96. The company's market cap stands at 80.7B, with a P/E ratio of 17.92 and a dividend yield of 47.0%.

On 2025-12-19, Regeneron(REGN) stock traded between a low of $748.18 and a high of $773.85. Shares are currently priced at $767.96, which is +2.6% above the low and -0.8% below the high.

The Regeneron(REGN)'s current trading volume is 2.33M, compared to an average daily volume of 915.41K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $790.98 and a 52-week low of $476.49.

In the last year, Regeneron(REGN) shares hit a 52-week high of $790.98 and a 52-week low of $476.49.

REGN News

TipRanks 11h
Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical (TEVA) announced that they have reached a settlement and license agreement wit...

Simply Wall St 2d
Regeneron Valuation Check After Lynozyfic Trial Success and New Gene Writing Collaboration

Regeneron Pharmaceuticals (REGN) has caught investors attention after unveiling promising Phase 1/2 data for its multiple myeloma candidate Lynozyfic, along wit...

Regeneron Valuation Check After Lynozyfic Trial Success and New Gene Writing Collaboration
Simply Wall St 3d
Is Regeneron Still Attractively Priced After Its Recent Share Price Surge?

If you are wondering whether Regeneron Pharmaceuticals is still worth considering after its big run, or if most of the upside is already reflected in the price,...

Is Regeneron Still Attractively Priced After Its Recent Share Price Surge?

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
30%
Sell
3.3%

More REGN News

Nasdaq 4d
Benjamin Graham Detailed Fundamental Analysis - REGN

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...

Benjamin Graham Detailed Fundamental Analysis - REGN
TipRanks 5d
Regeneron Initiates Promising Phase 2 Study on Diabetic Kidney Disease

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backe...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.